Eton Pharmaceuticals (NASDAQ:ETON) Given New $18.00 Price Target at Craig Hallum

Eton Pharmaceuticals (NASDAQ:ETON) had its target price lifted by Craig Hallum from $15.00 to $18.00 in a research report report published on Wednesday morning,Benzinga reports. Craig Hallum currently has a buy rating on the stock.

Separately, HC Wainwright increased their target price on Eton Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday.

Eton Pharmaceuticals Stock Up 0.2 %

NASDAQ ETON opened at $12.01 on Wednesday. The firm has a market cap of $312.87 million, a P/E ratio of -54.59 and a beta of 1.38. The company’s 50 day moving average is $11.57 and its 200-day moving average is $7.32. Eton Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $15.00.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ETON. Westside Investment Management Inc. grew its stake in Eton Pharmaceuticals by 5.7% during the third quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock valued at $3,711,000 after acquiring an additional 33,275 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Eton Pharmaceuticals by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock valued at $1,637,000 after purchasing an additional 32,365 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Eton Pharmaceuticals in the third quarter worth $90,000. Parkman Healthcare Partners LLC increased its holdings in shares of Eton Pharmaceuticals by 2.8% in the third quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock worth $1,561,000 after purchasing an additional 7,029 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Eton Pharmaceuticals in the third quarter worth $54,000. 27.86% of the stock is currently owned by institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.